Navelbine
(Vinorelbine Tartrate)Phase 3Small molecule
Vinorelbine tartrate is a chemotherapy drug used to treat certain types of cancer, particularly lung cancer and breast cancer, by stopping cancer cells from dividing and growing.[1] Navelbine is currently being investigated across 3 indications[3], with its most advanced program in Phase 3.[1]
Navelbine is one of 96 small molecule programs targeting Breast Cancer. It is currently in Phase 3.
3
Indications
80
Total Trials
9
Active Trials
95
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Navelbine
PPierre Fabre Medicament
Phase 3
Lexiscan
AstellasPreclinical
Tianeptine
PfizerPreclinical
Diuretic
RReprieve Cardiovascular, Inc
Preclinical
Recombinant Human Endostatin
PPeking University Third Hospital
Preclinical
Naltrexone/bupropion
Novo NordiskPreclinical
Sertraline ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Motexafin Gadolinium
PPharmacyclics LLC.
Preclinical
Perflutren Lipid Microsphere
IImaRx Therapeutics
Preclinical
QBX258
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer24 trials
Show 21 more trials
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
Unknown status·—·Phase 2·NCT00083083·250 enrolled
Vinorelbine and/or Gemcitabine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Unknown status·IIstituto Nazionale per lo Studio e la Cura dei Tumori·Phase 3·NCT00003447·630 enrolled
Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Unknown status·—·Phase 2·NCT00005825
Breast Cancer22 trials
Vinorelbine Plus Fluorouracil in Treating Women With Metastatic Breast Cancer
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·N/A·NCT00003730·80 enrolled
Show 19 more trials
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT06255392·200 enrolled
Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT05823623·30 enrolled
DP303c in Patients With HER2-positive Advanced Breast Cancer
Not yet recruiting·
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 3·NCT05901935·420 enrolled
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 3·NCT05901935·420 enrolledCapecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer
Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2/3·NCT00049660·47 enrolled
A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain
Terminated·—·Phase 2·NCT00476827·16 enrolled
Lymphoma9 trials
Show 6 more trials
Metastatic Prostate Cancer5 trials
Rhabdomyosarcoma4 trials
Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma
Unknown status·EEuropean Paediatric Soft Tissue Sarcoma Study Group·Phase 3·NCT00379457·600 enrolled
16 more indications
Advanced Cancer1 trial
Chemotherapy1 trial
Radiation Therapy1 trial
Hematologic Malignancies1 trial
Cervical Cancer1 trial
Kidney Cancer1 trial
Malignant Mesothelioma1 trial
Malignant Pleural Mesothelioma1 trial
Acute Leukemia1 trial
Brain Metastases1 trial
Advanced Solid Tumors1 trial
Regulatory
FDA Approval Timeline[4]
Dec 23, 1994
NAVELBINE
NDA NDA020388
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Vinorelbine Tartrate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Tubulin Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- PPierre Fabre Medicament